AML with 11q23 abnormalities involving the MLL gene comprise one category of recurring genetic abnormalities in the WHO-classification. In an unselected series of 1897 AML cases 54 patients with an 11q23/MLL rearrangement were identified resulting in an incidence of 2.8%. The incidence of AML with MLL-rearrangement was significantly higher in t-AML than in de novo AML (9.4% vs. 2.6%, p<0.0001). The frequency of MLL-rearrangements was significantly higher in patients younger than 60 years (5.3% vs. 0.8%, p<0.0001). While the incidence of MLL-rearrangements in AML M4, M5a and M5b was 4.7%, 33.3% and 15.9% respectively, it was found in only 0.9% of all other FAB subtypes (p<0.0001). In comparison to AML with intermediate karyotype, AML with 11q23/MLL rearrangement had a worse outcome, which was rather comparable to AML with unfavorable karyotype. Compared to t-AML the median overall survival (OS) of de novo AML with MLL rearrangement was significantly better (2.5 vs. 10 months, p=0.0143). No significant differences in median OS were observed between cases with t(9;11) compared to all other MLL rearrangements (10.0 vs. 8.9 months, p=0.36). In conclusion, the category AML with 11q23/MLL abnormalities accounts for 2.8% of unselected AML, is closely associated with monocytic differentiation and has a dismal prognosis. claudia
INTRODUCTION
Classification of acute myeloid leukemia (AML) has been based on cytomorphology and cytochemistry since the introduction of the FAB classification in 1976. 1 As other techniques like immunophenotyping as well as cytogenetics and moleculargenetics contributed to the definition of AML subtypes the FAB classification was updated accordingly. [2] [3] [4] [5] In parallel the MIC classification was published in 1986, which used morphology, immunophenotype and cytogenetics to define subgroups in AML. 6 This system already proposed a category M5a/t(11q), although no detailed studies are quoted to underline this decision. In 1999/2001 the WHO classification for tumors of hematopoietic and lymphoid tissues was proposed. 7 In an attempt to define biological homogenous entities which have clinical relevance morphologic, immunophenotypic, genetic and clinical features were incorporated in the classification of AML. 8 The WHO classification of AML encompasses four major categories: AML with 11q23/MLL abnormalities is heterogeneous due to the different partner chromosomes/partner genes. More than 50 partners of the MLL gene have been described and more than 30 partner genes have already been cloned and analyzed at the molecular level. 9 ; 10 Therefore, it was the aim of this study to characterize this subcategory of AML on the basis of a series of 1897 unselected and cytogenetically analyzed AML at diagnosis with special emphasis on the overall incidence, the different partner chromosomes, FAB subtype, age distribution and prognostic impact.
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MATERIAL AND METHODS

Patient Material
Between January 1996 and August 2001 1897 patients with newly diagnosed AML cytogenetics were successfully performed in our laboratory and were the basis for this study without any further selection. This cohort represents 98.2% of all AML cases sent to our laboratory for cytogenetic analysis. 1.8% were scored not evaluable because no or only an insufficient number of metaphases was obtained (less than 15 metaphases if no clonal chromosome abnormalities were detected). Altogether 54 cases with an 11q23 abnormality involving the MLL gene were identified. In each case the rearrangement of the MLL gene was proven either by RT-PCR and/or FISH with a MLL probe.
Treatment
Fifty-four of 92 patients (58.7%) with t-AML and 1037 of 1091 cases (95.1%) with de novo AML were treated within the AMLCG trials 1992 and 1999 or AMLCG APL trial while the others were treated with comparable therapies. 11; 12 In detail, patients within the AMLCG 1992 trial received the following treatment. For remission induction patients were treated according to the double induction strategy. The first course consisted of the TAD. The HAM course was scheduled to be started on day 21 unless patients had severe life-threatening non-hematologic toxicity in case of which chemotherapy was postponed until resolution of toxicity. The second course of the double induction therapy was applied to patients older than 60 years only if they had residual leukemic blasts of five percent or more in the bone marrow on day 16. Consolidation therapy consisted of one course of TAD which was applied two to four weeks after achievement of complete remission. Patients under age 60 with HLA-identical sibling donors subsequently underwent allogeneic bone marrow or peripheral blood stem cell transplantation. All other patients received further treatment according to the randomization performed at study entry.
Patients were randomized upfront to three years of myelosuppressive maintenance therapy or to a second course of intensive consolidation therapy following TAD-consolidation, For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From respectively. The second course of consolidation therapy consisted of the sequential highdose AraC and mitoxantrone (S-HAM). The dose per application of HDAraC was 1 g/m 2 in patients younger than 60 years and 500 mg/m 2 in older patients.
Patients treated within the AMLCG 1999 trial received the identical treatment as described for the 1992 trial with regard to induction and post-remission therapy with the following exceptions: Patients were randomized 1) to receive TAD/HAM or HAM/HAM as double induction therapy and 2) to receive autologous stem cell transplantation or three years of maintenance after consolidation therapy (patients under age 60 only; all patients 60 years received maintenance treatment). In addition, patients from 25 of the 52 participating study centers were randomized to receive or not priming with G-CSF two day before and during chemotherapy.
Cytomorphology
In 1293 of the 1897 patients cytomorphological analysis based on FAB criteria was carried out in parallel in the same laboratory. In total, FAB subtypes were available in 1490 cases.
Cytogenetics
Bone marrow or peripheral blood cells were cultured in RPMI 1640 medium supplemented with 20% fetal calf serum at 37°C for 24h and 48h. Unstimulated as well as cytokine stimulated cultures as described elsewhere were performed in parallel. was performed in a 50 µl reaction using 300 U Superscript II (GibcoBRL/Invitrogen, Karlsruhe, Germany) and random hexamer primers (Pharmacia, Freiburg, Germany). MLLfusion transcripts were amplified as described previously. [15] [16] [17] [18] For each sample an ABL specific RT-PCR was performed to control the integrity of DNA or RNA as described. 19 Water instead of cDNA was included as a blank sample in each experiment. Amplification products were analyzed on 1.5% agarose gels stained with ethidium bromide.
Strict precautions were taken to prevent contamination. Water instead of cDNA was included as a blank sample in each experiment. Amplification products were analyzed on 1.5%
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Statistics
Overall survival (OS) was defined as time from start of therapy until death and was calculated according to 20 and the differences between groups were analyzed using the log-rank statistics. 21 Patients receiving bone marrow transplantation were not censored at bone marrow transplantation. Multivariate analysis was performed applying the Cox model. All calculations were performed using SPSS 11.01.
RESULTS
Incidence of 11q23/MLL rearrangements in de novo AML vs. t-AML vs. AML after an antecedent hematological disorder
AML occurred de novo in 1632 patients (86%), after an antecedent hematological disorder in 148 (7.8%), and was therapy-related in 117 cases (6.2%). In 54 AML an 11q23 rearrangement was identified by chromosome banding analysis and an involvement of the MLL gene was confirmed by FISH analysis and/or RT-PCR in all cases. Therefore, the incidence was 54/1897 (2.8%). Forty-three cases were de novo AML and 11 cases were t-AML. Preceding tumors in patients with t-AML were Hodgkin's disease (n=3), breast cancer (n=2), testicular cancer (n=2), gastric cancer (n=1), thymoma (n=1), neuroendrocrine tumor (n=1) and Non-Hodgkin's lymphoma (n=1). The median latency period between therapy for the primary tumor and diagnosis of t-AML was 24 months (range 9-100 months). The incidence of AML with MLL-rearrangement was significantly higher in t-AML than in de novo AML (9.4% vs. 2.6%, p<0.0001). No case with 11q23/MLL rearrangement occurred in AML after an antecedent hematological disorder.
Correlation with cytomorphology
FAB subtype distribution of cases with 11q23/MLL rearrangement was: M0: 1, M1: 4, M2: 4,
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From M4: 11, M5a: 20, M5b: 11, no data: 2 and did not differ between de novo AML and t-AML (figure 1). In total 81% showed an involvement of the monocytic lineage. While the incidence of MLL-rearrangement in AML M4, M5a and M5b was 4.7%, 33.3% and 15.9% respectively, it was found in only 0.9% of all other FAB subtypes (p<0.0001). Table 1 the FAB subtype distribution in the whole AML cohort is compared to AML with an 11q23/MLL rearrangement.
Age distribution
The median age of cases with 11q23/MLL-rearrangements was 48.5 years (48 years in de novo AML, 53 years in t-AML, range 14-74 years), while in the total cohort the median age was 57.9 years (range 14-84 years). Thus, the incidence of MLL-rearrangements was significantly higher in patients younger than 60 years (5.3% vs. 0.8%, p<0.0001). The age distribution in AML with MLL-rearrangement as compared to the total cohort of AML is shown in table 2.
Partner chromosomes
The partner chromosomes of the MLL gene in the 54 cases were 9p22 (n=19; 35.2%), For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From 10p12 (n=8; 14.8%), 6q27 (n=5; 9.3%), 19p13 (n=5; 9.3%), 17q21 (n=4; 7.4%), 17q25 (n=3; 5.6%), 1q21 (n=2; 3.7%), 15q15 (n=2; 3.7%), 22q12 (n=2; 3.7%) and 2q37, 10q22, 12q24 and 14q32 in one case each (1.9%). In table 3 the different partner chromosomes are shown for de novo AML and t-AML as well as the distribution with respect to age and FAB subtype.
No specific association was observed between partner chromosomes and de novo vs. t-AML or age or FAB subtype. Table 4 provides information on the respective fusion genes as assessed by RT-PCR. FISH was carried out with whole chromosome painting probes for chromosomes 11 and the respective partner chromosome in those cases without an amplifiable fusion gene to prove the partner chromosome.
Additional chromosome aberrations
In 22 cases additional chromosome abnormalities were observed. More than two additional abnormalities were found in 8 cases (in 3 cases only gains of whole chromosomes, in 5 cases numerical and structural abnormalities). Karyotypes of the 22 cases with abnormalities in addition to the translocation involving the MLL gene are shown in table 5. Recurring additional abnormalities were +8 (n=10), +6 (n=3), +20 (n=3), -7 (n=3) and del(3)(q21) (n=2).
One of 11 t-AML (9%) and 21 of 43 de novo AML (48.9%) showed additional chromosome aberrations.
Clinical outcome
For 51 of 54 patients with MLL rearrangement and for 1132 of 1843 AML cases without an MLL rearrangement clinical follow-up data were available. Median follow-up time was 16 months (range 1 to 75 months). Patients with clinical follow-up data were younger and more frequently had favorable karyotype characteristics as compared to cases without available clinical follow-up data (table 6). Two cases with t(9;11) and 5 patients with other 11q23/MLLrearrangements received an allogeneic stem cell/bone marrow transplantation (6 in first complete remission, 1 case with a t(1;11) in second complete remission).
AML without MLL rearrangement were grouped according to karyotype into 4 categories: (table 7) . A multivariate analysis confirmed the prognostic impact of all these parameters (table 8).
In univariate Cox regression analyses of overall survival in the cohort of patients with unfavorable karyotypes or with 11q23/MLL-rearrangements using age, white blood cell count, 11q23/MLL-rearrangements (vs. unfavorable karyotype), and t-AML (vs. de novo AML) as covariates only age and t-AML were significantly correlated with overall survival (p<0.001 and p=0.032, respectively). This was confirmed in a multivariate analysis (p<0.001, and p=0.031, respectively).
Further evaluations were performed within the cohort of AML with 11q23/MLLrearrangements. In univariate Cox regression analysis for overall survival using age, white blood cell count, t(9;11) (vs. other 11q23/MLL-rearrangements), additional abnormalities (vs. no additional abnormalities), and t-AML (vs. de novo AML) as covariates only t-AML was significantly correlated with overall survival (p=0.01). If only de novo AML were analyzed all other parameters were also not significant. The median overall survival of AML de novo with MLL rearrangement was 10 months as compared to 2.5 months in t-AML with MLL rearrangement (p=0.0143, figure 3 ). The median overall survival was 10.0 months in cases with t(9;11) as compared to 8.9 months in AML with other MLL rearrangements in the whole group (p=0.36, figure 4). Median age was 47 years (range 18-67) in AML with t(9;11) and 46 years (range 18-65) in AML with other MLL rearrangements. The median white blood cell count was 27,450/µl (range 250-220,000) in t(9;11) cases and 24,550/µl (range 740- 
DISCUSSION
The MLL gene is fused to a large variety of more than 50 different partner genes in acute myeloid leukemia. 10 In childhood as well as in adult leukemia t(9;11) is the most frequent translocation involving the MLL gene and accounts for about one third of cases with MLL rearrangement. 22; 23 In t-AML an even higher proportion of 9p22 as translocation partner (48%) has been reported. 24 Rearrangements involving AF10 on the short arm of chromosome 10 are observed in 15-20% in de novo AML with MLL rearrangement but were only reported in 1% of t-AML in a large series. 24 All other partner genes are found with lower For personal use only. on November 16, 2017. by guest www.bloodjournal.org From frequencies. Partner genes in 19p seem to be more frequently involved in t-AML than in de novo AML. 24 In our large series of 54 AML cases with proven MLL rearrangement 13 different partner genes were observed.
Clonal chromosome aberrations in addition to the 11q23-rearrangement were observed in 41% of our total cohort and in 48.8% of de novo AML. This frequency is comparable to data reported in other adult and childhood series. 22; 23; 25 The most frequently reported additional aberration is trisomy 8.
22; 26
With regard to cytomorphology, our data confirm the correlation of 11q23/MLL rearrangements with AML of the monocytic lineage; however, also single cases with AML M0, M1 and M2 were detected. A correlation between the partner chromosomes and FAB subtypes was not observed in our series.
Based on their recent evaluation on the prognostic impact of cytogenetics the CALGB assigned cases with t(9;11) to the intermediate group while cases with other balanced 11q23-abnormalities were grouped as unfavorable. 27 Evaluation of two other large trials from the MRC in younger and in elderly patients revealed that patients with 11q23 abnormalities showed an intermediate outcome with an overall survival rate of 45% at 5 years (n=60, median age 17 years) in the younger cohort and an overall survival rate of 0% at 5 years (n=11, median age 64 years) in the cohort of elderly cases. 28; 29 In contrast, in a combined analysis of SWOG and ECOG trials including adult patients (age 16-55) 11q abnormalities were assigned to the unfavorable cytogenetic subgroup. 30 Our data show that in de novo AML patients with 11q23/MLL rearrangements show a worse outcome as compared to the intermediate group. Their prognosis is rather comparable to the unfavorable group.
We found that the median overall survival of patients with t(9;11) was not significantly different from patients with other MLL rearrangements both in de novo and in t-AML. This is in contrast to data from the CALGB indicating a median overall survival of 13.2 months in 23
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From cases of t(9;11) compared to 7.7 months in 24 cases with other 11q23 rearrangements (p=0.009). 25 In a recent update of this series of AML from CALGB including 54 cases with balanced 11q23 rearrangements 27 cases with t(9;11) showed a median overall survival of 13 months compared to 7.2 and 8.4 months for cases with other partner genes of 11q23.
Based on these differences t(9;11) cases were assigned to the intermediate group and the other 11q23 rearrangements to the unfavorable cytogenetic group. 27 In our cohort of de novo AML 14 cases with t(9;11) had a median overall survival of 10.0 months compared to 12. In a collaborative analysis of 108 patients with AML and t(9;11) prognosis was related to age with children 1 to 14 years old showing a more favorable outcome, than infants and adults 15 to 49 years of age, the poorest outcome was observed in patients 50 years and older. 22 With respect to age the CALGB cohort does not differ from our cohort (median age in cases with t(9;11) 44 years and in cases with other 11q23 translocations 39 years as compared to 47 and 46 years, respectively). Rubnitz et al. compared the outcome of t(9;11) positive cases vs. other 11q23/MLL-rearrangements in childhood AML. They observed a more favorable outcome in cases with t(9;11) than in patients with other 11q23/MLLrearrangements (EFS at 5 years 65% (n=23) vs. 24% (n=33)). 23 But also in childhood AML results vary. In a large trial of the Pediatric Oncology Group no differences in outcome was
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From observed between cases with t(9;11) and cases with other 11q23/MLL-rearrangement. Both groups showed a quite poor outcome. 35 The differences observed so far within the different published trials with respect to the prognostic impact of t(9;11) vs. other 11q23 translocations might be due to the still small number of patients or the impact of different therapy protocols. Especially the impact of allogeneic bone marrow or stem cell transplantation on prognosis of cases with 11q23/MLL-rearrangement has to be further evaluated as it has been reported that in younger patients those with an HLA identical donor had a better outcome compared to those without a donor, especially in patients with unfavorable cytogenetics. 36 Whether the reported differences in outcome between cases with t(9;11) vs. other 11q23/MLL-rearrangements reflect differences in the frequency of allogeneic transplantation in the respective trials remains unclear as the number of reported patients who received an allograft is low in most series.
In our series a significant difference in outcome was demonstrated in AML with 11q23/MLL rearrangement between de novo and therapy related cases. Karyotype abnormalities in addition to the 11q23/MLL-rearrangement had no influence on prognosis. This confirms the data of Byrd et al. who showed a comparable outcome in cases with t(9;11) with and without additional aberrations. 27 In t-AML no differences in overall survival according to partner genes were reported, but patients with additional karyotype abnormalities showed a worse outcome. 24 Fro m a morphological and a cytogenetic point of view AML with 11q23/ MLL translocations are more heterogeneous than AML with t(8;21), AML with t(15;17), and AML with inv(16)/t(16;16). Furthermore MLL rearrangements also occur in acute lymphoblastic leukemia. Therefore, it can be speculated that they do not comprise a biologic entity.
However, it has been shown in AML as well as in ALL that cases with MLL-rearrangements have specific gene expression profiles which allow the distinction from other ALL subtypes as well as from other AML subtypes. 37; 38 The ALL-MLL group included cases with at least 5 different translocation partners, while in the analysis of AML the 15 cases with 11q23/MLL-
39; 40 Therefore, it seems appropriate to regard AML with 11q23/MLL rearrangement as an entity as suggested by WHO as long as no clear data are available which give evidence for major differences in biology. This is in line with the distinct clinical outcome which has been demonstrated in the present analysis.
In addition to rearrangements with a large variety of different partner genes MLL rearrangements can be found within MLL as the result from partial tandem duplication (MLL-PTD) usually spanning exons 3 through 9 or exons 3 through 11, which are also mentioned in the WHO classification. Translocations of the MLL gene and MLL-PTD seem to be mutually exclusive as they do not occur together. 41 In contrast to AML with translocations involving MLL AML with MLL-PTD usually are not associated with a typical morphology.
41-44
Clinical outcome in this AML subgroup is also unfavorable. 42; 43; 45 Similar to translocations of 11q23 involving the MLL-gene the MLL-PTD occurs significantly more frequently in AML secondary to a previous cytotoxic therapy. In a study analyzing AML with normal karyotype with MLL-PTD (n=10) and AML with MLL-translocations (n=15) using gene expression analysis, differentially expressed genes were identified which allowed a clear distinction between both AML subtypes. 46 Therefore, both groups have to be regarded as two different entities.
In conclusion, the present data suggest that AML with 11q23/MLL rearrangement and different partner genes seems to comprise a biologically and clinically homogeneous entity 
